BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that on January 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,900 shares of common stock and 12,000 restricted stock units to four new employees under Mirum’s 2020 Inducement Plan.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 and MN-002 for the treatment of scleroderma and/or systemic sclerosis.

BioArctic AB’s partner Eisai announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease and mild AD dementia) to the European Medicines Agency.